<DOC>
	<DOC>NCT00170664</DOC>
	<brief_summary>The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.</brief_summary>
	<brief_title>Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histologicallyconfirmed epithelial ovarian cancer of FIGO stage IIB IV life expectancy of more than three months ECOG performance status less than 3 laboratory parameters within the normal range, including a glomerular filtration rate (GFR) greater than 60 ml/min, serum creatinine levels below 1.6 mg/dl, liver transaminases less than two times the normal levels, bilirubin concentrations below 1.5 mg/dl, adequate bone marrow function as indicated by a neutrophil count greater than 1,500/µl, and a platelet count greater than 100,000/µl. written informed consent suffering from secondary malignancy or underlying serious, uncontrolled concurrent medical or psychiatric disease radiotherapy within 4 weeks for study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ovarian neoplasms</keyword>
	<keyword>paclitaxel, carboplatin</keyword>
	<keyword>clinical trials, phase II</keyword>
	<keyword>first-line chemotherapy</keyword>
	<keyword>weekly therapy schedule</keyword>
</DOC>